RxDoctor Payments Data

Hristelina Ilieva, MD

Neuromuscular Medicine · Philadelphia, PANPI 1598076358

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Akcea Therapeutics, Inc. accounts for 77.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $4,231 and has fallen 88.2% since, to $500 in 2024.

$5,238in general payments, 2019–2025

Across 30 payments — averaging $174.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akcea Therapeutics, Inc.$4K
  • AstraZeneca$491
  • Alnylam Pharmaceuticals Inc.$305
  • CSL Behring$116
  • Argenx US, Inc.$100
  • Biogen$52
  • plus $97 from 3 others
$381,626in research payments, 2019–2025

Across 68 payments — averaging $5612.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$95K
  • Tanabe Pharma America, Inc.$86K
  • Akcea Therapeutics, Inc.$80K
  • UCB SA$51K
  • Mitsubishi Tanabe Pharma Development America, Inc.$41K
  • Biohaven Pharmaceutical Holding Company Ltd.$18K
  • plus $11K from 1 others

What the payments were for

  • Speaking & faculty fees$2,82054%
  • Travel & lodging$77315%
  • Food & beverage$1,56530%
  • Education$802%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromuscular medicine providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$34,657
Medicare patients
119
Services billed
406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AmvuttraVutrisiran Sodium32$3,775,536
WainuaEplontersen Sodium16$877,218
Radicava OrsEdaravone25$333,566
Riluzole100$43,575
Scopolamine13$1,412
Pyridostigmine Bromide23$1,162
Gabapentin80$711
Atropine Sulfate14$669
Mirtazapine33$578
Baclofen33$496
Pregabalin19$263
Duloxetine Hcl13$240
Sertraline Hcl16$212
Prednisone14$204
Lorazepam11$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alnylam Pharmaceuticals Inc.Amvuttra$305$3,775,53632 claims
AstraZenecaWainua$491$877,21816 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$35$1,16223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.

Other neuromuscular medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →